Manufacturer or GPO Program year 2025 Source: CMS Open Payments

CMP Pharma, Inc.

NC, United States

CMS manufacturer 100000556811

Open in the dashboard

General payments

$110,977

2,775 payments

Research payments

$1,474

4 payments

Ownership & investment interest

$0

None reported

Through program year 2025, CMP Pharma, Inc. reported paying $110,977 in general payments and $1,474 in research payments to U.S. physicians, teaching hospitals and other recipients.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

9 rows
Year Kind Amount Payments
2025 General $2,110 92
2025 Research $1,068 2
2024 General $3,666 110
2024 Research $406 2
2023 General $31,943 650
2022 General $34,735 905
2021 General $34,977 868
2020 General $2,318 124
2019 General $1,228 26

Breakdown

Top recipients General payments · program year 2025
  1. John Lai Internal Medicine · Daly City, CA $222 9 payments
  2. Navdeep Bamrah Nurse Practitioner, Family · San Jose, CA $220 10 payments
  3. Shashwati Kale Family Medicine · San Jose, CA $181 8 payments
  4. Kevin Wong Internal Medicine · Daly City, CA $161 6 payments
  5. Susan Hoffman Internal Medicine · Palo Alto, CA $149 7 payments
  6. Jeffrey Croke Internal Medicine · Palo Alto, CA $148 7 payments
  7. Kathryn Renschler Internal Medicine · Palo Alto, CA $122 5 payments
  8. Julie Wissink Internal Medicine · Palo Alto, CA $76 3 payments
  9. Pneuma Ortega Family Medicine · San Jose, CA $70 3 payments
  10. William Chu Internal Medicine · Palo Alto, CA $68 3 payments
Top research recipients Research payments · program year 2025
  1. The Childrens Hospital Of Philadelp Teaching hospital · PA $1,068 2 payments
Products the payments named General payments · program year 2025
  1. Atorvaliq Cholesterol $2,110 20% · 40 recipients
  2. CaroSpir Cardiology $2,110 20% · 40 recipients
  3. Liqrev Pulminary Arterial Hypertension - PAH $2,110 20% · 40 recipients
  4. Norliqva calcium channel blocker liquid $2,110 20% · 40 recipients
  5. Tadliq Pulmonary Arterial Hypertension $2,110 20% · 40 recipients

Each share is of this company’s general payments naming a product in 2025. A payment can name up to five products, so these amounts overlap.

Specialties paid General payments · program year 2025
  1. Internal Medicine $946 45% · 7 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $382 18% · 8 practitioners
  3. Family Medicine $276 13% · 3 practitioners
  4. Nurse Practitioner $76 4% · 4 practitioners
  5. Physician Assistant, Medical Physician Assistant $53 3% · 1 practitioner

The top 5 of 19 specialties; each share is of this company’s general payments to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $1,569 74% · 15 recipients
  2. Arizona $200 9% · 9 recipients
  3. Texas $168 8% · 7 recipients
  4. Maryland $149 7% · 8 recipients
  5. Delaware $24 1% · 1 recipient

Each share is of this company’s general payments in 2025 where a state was reported.

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $73,402 2,712 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,525 60 payments
  3. Consulting Fee $7,050 3 payments
2,775 general · 4 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record